Coloplast (COLO B) Panoramica del titolo
Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 5/6 |
Premi
Analisi del rischio
COLO B Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Coloplast A/S
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | DKK 443.80 |
| Massimo di 52 settimane | DKK 646.60 |
| Minimo di 52 settimane | DKK 369.70 |
| Beta | 0.55 |
| Variazione di 1 mese | 6.07% |
| Variazione a 3 mesi | 7.25% |
| Variazione di 1 anno | -29.62% |
| Variazione a 3 anni | -44.36% |
| Variazione a 5 anni | -59.56% |
| Variazione dall'IPO | 3,373.22% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
Aggiornamento narrativa • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.Recent updates
Aggiornamento narrativa • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.Aggiornamento narrativa • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
Aggiornamento narrativa • Jun 16
COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating
The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.Aggiornamento narrativa • Jun 02
COLO B: New CEO And Lower P/E Will Support Future Multiple Re Rating
The updated analyst price target for Coloplast moves from DKK 500.15 to DKK 461.90, as analysts factor in slightly firmer revenue growth assumptions, a small change in the discount rate, and a lower future P/E multiple, while recent research highlights both reduced targets and one new Buy initiation after the share selloff. Analyst Commentary Recent Street research on Coloplast reflects a mix of optimism and caution, with several firms adjusting price targets and ratings following the share selloff.Articolo di analisi • May 20
Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings
Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...Articolo di analisi • May 15
Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...Aggiornamento narrativa • May 10
COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating
The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target.Aggiornamento narrativa • Apr 24
COLO B: New CEO Appointment Will Underpin Future Multiple Re Rating Potential
Coloplast's analyst price target has been nudged lower to about DKK 552 from roughly DKK 561, reflecting recent cuts to DKK-based targets by several banks as analysts factor in a slightly higher discount rate, a modestly adjusted future P/E assumption and only small tweaks to long term growth and margin expectations. Analyst Commentary Recent Street research around Coloplast has centered on recalibrated price targets and rating changes as analysts reassess what they are willing to pay for the company, given updated discount rates and P/E assumptions.Aggiornamento narrativa • Apr 09
COLO B: New CEO Appointment Will Support Future Re Rating Potential
The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.Aggiornamento narrativa • Mar 26
COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating
Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.Aggiornamento narrativa • Mar 11
COLO B: Reset P/E And New Leadership Will Support Future Re Rating
The updated analyst price target for Coloplast has been trimmed by around DKK 9 to reflect lower Street targets. This includes cuts to DKK 504 at Deutsche Bank and reductions at RBC Capital, JPMorgan and Berenberg, as analysts factor in slightly higher discount rates, modestly softer margin assumptions and a lower future P/E multiple.Aggiornamento narrativa • Feb 25
COLO B: Reset P/E And Dividend Will Support Future Re Rating
Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.Aggiornamento narrativa • Feb 10
COLO B: Reset P/E And Dividend Will Support Future Upside
Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.Articolo di analisi • Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...Aggiornamento narrativa • Jan 24
COLO B: Dividend Reliability And Premium P/E Will Support Future Upside
Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.Aggiornamento narrativa • Jan 09
COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside
Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.Aggiornamento narrativa • Dec 13
COLO B: Sustained Margin Strength Will Support Upside As Dividend Payouts Increase
Analysts have nudged our Coloplast fair value estimate slightly higher to about DKK 689 per share from roughly DKK 689 previously, reflecting a modest uptick in long term multiple assumptions even as recent Street price target revisions have moved in mixed directions. Analyst Commentary Recent Street actions on Coloplast highlight a divided view on near term upside versus longer term execution and growth.Articolo di analisi • Dec 04
Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00
Coloplast A/S ( CPH:COLO B ) has announced that it will be increasing its dividend from last year's comparable payment...Aggiornamento narrativa • Nov 29
COLO B: Sustained Margin Strength Will Support Upside Amid Market Challenges
Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.Articolo di analisi • Nov 20
Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00
Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...Aggiornamento narrativa • Nov 14
COLO B: Future Execution In Core Markets Will Drive Share Price Momentum
The analyst consensus price target for Coloplast has modestly decreased. Updated projections reflect cautious sentiment from analysts, who cite modest adjustments to growth and profitability expectations.Aggiornamento narrativa • Oct 31
COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance
Coloplast’s analyst price target was reduced slightly from DKK 691.83 to DKK 686.00, as analysts cite modestly lower revenue growth expectations and recent target decreases across several major firms. Analyst Commentary Recent commentary from market analysts highlights a balanced perspective on Coloplast’s outlook, with both raised and lowered price targets reflecting shifting sentiment in key performance areas.Aggiornamento narrativa • Oct 17
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been reduced by nearly DKK 10 to DKK 691.83. Analysts cite mixed recent revisions in target prices, reflecting a balanced outlook amid evolving growth and margin expectations.Aggiornamento narrativa • Oct 03
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been revised downward from DKK 716 to DKK 701. Analysts have adjusted their expectations in response to a series of recent target reductions following tempered growth and margin forecasts.Aggiornamento narrativa • Aug 30
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.Articolo di analisi • Aug 22
Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next
It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...
Nuova narrativa • Nov 07
Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth
Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.Rendimenti per gli azionisti
| COLO B | DK Medical Equipment | DK Mercato | |
|---|---|---|---|
| 7D | 3.3% | 2.2% | 0.8% |
| 1Y | -29.6% | -17.4% | -0.2% |
Ritorno vs Industria: COLO B ha avuto una performance inferiore rispetto al Danish Medical Equipment che ha registrato un rendimento -17.4 % nell'ultimo anno.
Rendimento vs Mercato: COLO B ha avuto una performance inferiore al mercato Danish che ha registrato un rendimento -0.2 % nell'ultimo anno.
Volatilità dei prezzi
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in DK Market | 7.1% |
| 10% least volatile stocks in DK Market | 2.4% |
Prezzo delle azioni stabile: COLO B non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Danish.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di COLO B è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1954 | 17,213 | Gavin Wood | www.coloplast.com |
Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale. L'azienda opera attraverso i segmenti Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology e Advanced Wound Care. L'azienda fornisce prodotti per la cura delle stomie, tra cui SenSura Mio, che permette di adattarsi alle forme del corpo e di avere una discrezione ottimale per vari tipi di stomie, e soluzioni per la cura delle stomie SenSura, oltre ad accessori per stomie con il marchio Brava.
Coloplast A/S Riepilogo dei fondamenti
| COLO B statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | DKK 99.93b |
| Utili (TTM) | DKK 2.76b |
| Ricavi(TTM) | DKK 28.44b |
36.2x
Rapporto P/E3.5x
Rapporto P/SCOLO B è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| COLO B Conto economico (TTM) | |
|---|---|
| Ricavi | DKK 28.44b |
| Costo del fatturato | DKK 9.32b |
| Profitto lordo | DKK 19.12b |
| Altre spese | DKK 16.36b |
| Utili | DKK 2.76b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Nov 03, 2026
| Utile per azione (EPS) | 12.27 |
| Margine lordo | 67.23% |
| Margine di profitto netto | 9.71% |
| Rapporto debito/patrimonio netto | 170.8% |
Come si è comportato COLO B nel lungo periodo?
Vedi performance storica e confrontoDividendi
5.2%
Rendimento attuale del dividendo188%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/19 10:48 |
| Prezzo dell'azione a fine giornata | 2026/08/19 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Coloplast A/S è coperta da 42 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |